Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.12678 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective cohort study of real-world clinical practice.
EJHaem
December 2024
Johnson & Johnson Innovative Medicine Lisbon Portugal.
Objectives: To characterize variations in real-world treatment patterns in multiple myeloma (MM) in Portugal over a 5-year period.
Methods: A retrospective cohort multicenter study using secondary data of national hospital drug consumption database from 11 Portuguese public hospitals between 2017 and 2022.
Results: Number of MM-treated patients increased 53% over 5 years (from 825 to 1266 patients).
Light-Chain Myeloma Presented as Osseus Tumors: A Case Report.
J Investig Med High Impact Case Rep
December 2024
Brookdale University Hospital Medical Center, Brooklyn, NY, USA.
Light-chain multiple myeloma (LCMM) is a rare subtype of plasma cell neoplasm, usually linked to kidney involvement and lytic bone lesions. However, case presents as osseus tumors are very uncommon. A 63-year-old male patient complained of persistent rib pain.
View Article and Find Full Text PDFIsatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
J Clin Oncol
December 2024
Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a significant increase of minimal residual disease negativity (MRD-) rates after induction therapy. A total of 662 patients were randomly assigned to receive induction therapy with Isa-RVd (n = 331) or RVd (n = 329), followed by single or tandem autologous stem-cell transplant and second random assignment to maintenance with lenalidomide alone or Isa-lenalidomide.
View Article and Find Full Text PDFElotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Blood Adv
December 2024
Massachusetts General Hospital, Boston, Massachusetts, United States.
Elotuzumab is an approved monoclonal antibody targeting SLAMF7 on plasma and NK cells that enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed improved outcomes with the combination of pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory MM. We therefore studied adding elotuzumab to PVd (elo-PVd) in relapsed/refractory MM in a multicenter phase 2 trial.
View Article and Find Full Text PDFSurvival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison.
Future Oncol
November 2024
Bristol Myers Squibb, Princeton, NJ, USA.
Aims: Limited head-to-head data exist for daratumumab plus pomalidomide and dexamethasone (DPd) and non-pomalidomide-containing triplet regimens to treat relapsed/refractory multiple myeloma (RRMM). This study conducted population-adjusted indirect comparisons of overall survival (OS) for DPd vs. daratumumab, carfilzomib, and dexamethasone (DKd) and daratumumab, bortezomib, and dexamethasone (DVd).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!